• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

NICOLAS, DETERRED and KEYNOTE 799: focus on escalation of conventionally fractionated chemoradiotherapy by immune checkpoint inhibition in unresectable stage III non-small cell lung cancer.

作者信息

Manapov Farkhad, Kenndoff Saskia, Käsmann Lukas

机构信息

Department of Radiation Oncology, University Hospital Ludwig Maximilian University of Munich (LMU), Munich, Germany.

German Center for Lung Research (DZL), Partner Site Munich, Munich, Germany.

出版信息

Transl Lung Cancer Res. 2022 Apr;11(4):702-705. doi: 10.21037/tlcr-21-950.

DOI:10.21037/tlcr-21-950
PMID:35529786
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9073737/
Abstract
摘要

相似文献

1
NICOLAS, DETERRED and KEYNOTE 799: focus on escalation of conventionally fractionated chemoradiotherapy by immune checkpoint inhibition in unresectable stage III non-small cell lung cancer.尼古拉斯、DETERRED 和 KEYNOTE 799：聚焦于在不可切除的 III 期非小细胞肺癌中通过免疫检查点抑制来强化传统分割放化疗。
Transl Lung Cancer Res. 2022 Apr;11(4):702-705. doi: 10.21037/tlcr-21-950.
2
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.免疫检查点抑制剂联合放化疗治疗不可切除 III 期非小细胞肺癌。
Lung Cancer. 2019 Aug;134:259-267. doi: 10.1016/j.lungcan.2019.05.027. Epub 2019 May 29.
3
Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.计划靶区作为不可切除 III 期非小细胞肺癌患者接受放化疗联合及/或序贯免疫检查点抑制治疗后疾病进展的预测因素。
Invest New Drugs. 2022 Feb;40(1):163-171. doi: 10.1007/s10637-021-01143-0. Epub 2021 Aug 5.
4
Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era.免疫检查点抑制剂在不可切除 III 期 NSCLC 中的应用：PACIFIC 时代之后的挑战与机遇。
Lung Cancer. 2021 Jul;157:85-91. doi: 10.1016/j.lungcan.2021.05.009. Epub 2021 May 11.
5
Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.不可切除 III 期非小细胞肺癌放化疗后免疫相关肺炎及随后的免疫检查点阻断。
Clin Lung Cancer. 2020 Sep;21(5):e435-e444. doi: 10.1016/j.cllc.2020.02.025. Epub 2020 Mar 9.
6
Radiation Dose Escalation in Stage III Non-Small-Cell Lung Cancer.III 期非小细胞肺癌的放射剂量递增。
Front Oncol. 2011 Nov 30;1:47. doi: 10.3389/fonc.2011.00047. eCollection 2011.
7
Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer.不可切除的 IIIA 期和 IIIB 期非小细胞肺癌的放化疗新方法。
Oncologist. 2012;17(5):682-93. doi: 10.1634/theoncologist.2012-0020. Epub 2012 Apr 24.
8
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.nivolumab 联合标准一线放化疗方案同期用于 III 期非小细胞肺癌的安全性评价：ETOP NICOLAS 试验。
Lung Cancer. 2019 Jul;133:83-87. doi: 10.1016/j.lungcan.2019.05.001. Epub 2019 May 3.
9
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14).在局部晚期 IIIA-B 期 NSCLC 中，nivolumab 与标准同期放化疗联合应用的无进展生存期和总生存期：来自欧洲胸部肿瘤平台 NICOLAS Ⅱ期试验（欧洲胸部肿瘤平台 6-14）的结果。
J Thorac Oncol. 2021 Feb;16(2):278-288. doi: 10.1016/j.jtho.2020.10.129. Epub 2020 Nov 12.
10
Role of Surgical Intervention in Unresectable Non-Small Cell Lung Cancer.手术干预在不可切除的非小细胞肺癌中的作用
J Clin Med. 2020 Nov 29;9(12):3881. doi: 10.3390/jcm9123881.

引用本文的文献

1
The role of chemoradiotherapy and immunotherapy in stage III NSCLC.放化疗和免疫治疗在 III 期 NSCLC 中的作用。
Pathol Oncol Res. 2024 Apr 19;30:1611716. doi: 10.3389/pore.2024.1611716. eCollection 2024.
2
Real-world incidence and risk factors of pneumonitis in chemoradiation plus immune checkpoint inhibitors compared with chemoradiation alone in lung cancer: a retrospective cohort study.与单纯放化疗相比，放化疗联合免疫检查点抑制剂治疗肺癌时肺炎的真实世界发病率及危险因素：一项回顾性队列研究
Transl Lung Cancer Res. 2024 Jan 31;13(1):139-151. doi: 10.21037/tlcr-23-756. Epub 2024 Jan 12.
3
A retrospective comparative cohort study: concurrent versus consolidative immunotherapy with chemoradiotherapy in EGFR- or ALK-negative unresectable stage III non-small cell lung cancer.一项回顾性比较队列研究：EGFR或ALK阴性不可切除III期非小细胞肺癌同步与巩固免疫治疗联合放化疗。
Transl Lung Cancer Res. 2023 Nov 30;12(11):2209-2218. doi: 10.21037/tlcr-23-575. Epub 2023 Nov 4.
4
Gene expression profiling of circulating tumor cells captured by MicroCavity Array is superior to enumeration in demonstrating therapy response in patients with newly diagnosed advanced and locally advanced non-small cell lung cancer.微腔阵列捕获的循环肿瘤细胞的基因表达谱分析在证明新诊断的晚期和局部晚期非小细胞肺癌患者的治疗反应方面优于计数。
Transl Lung Cancer Res. 2023 Jan 31;12(1):109-126. doi: 10.21037/tlcr-22-314. Epub 2023 Jan 16.

本文引用的文献

1
Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a mutation.携带某种突变的III期非小细胞肺癌（NSCLC）患者的预后。
Transl Lung Cancer Res. 2021 Aug;10(8):3608-3615. doi: 10.21037/tlcr-21-177.
2
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.帕博利珠单抗联合同步放化疗治疗不可切除的局部晚期 III 期非小细胞肺癌：2 期 KEYNOTE-799 非随机试验
JAMA Oncol. 2021 Jun 4;7(9):1-9. doi: 10.1001/jamaoncol.2021.2301.
3
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14).在局部晚期 IIIA-B 期 NSCLC 中，nivolumab 与标准同期放化疗联合应用的无进展生存期和总生存期：来自欧洲胸部肿瘤平台 NICOLAS Ⅱ期试验（欧洲胸部肿瘤平台 6-14）的结果。
J Thorac Oncol. 2021 Feb;16(2):278-288. doi: 10.1016/j.jtho.2020.10.129. Epub 2020 Nov 12.
4
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.一项针对不可切除 III 期非小细胞肺癌患者在同期放化疗后行巩固性帕博利珠单抗治疗的 2 期临床试验：Hoosier Cancer Research Network LUN 14-179。
Cancer. 2020 Oct 1;126(19):4353-4361. doi: 10.1002/cncr.33083. Epub 2020 Jul 22.
5
Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179.与接受放化疗后巩固性派姆单抗治疗的 III 期 NSCLC 患者的改善预后相关的预测变量：印第安纳癌症研究网络 LUN 14-179 二期研究的亚组分析。
Clin Lung Cancer. 2020 May;21(3):288-293. doi: 10.1016/j.cllc.2019.06.009. Epub 2019 Jul 8.
6
Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC.不可切除非小细胞肺癌的同步阿特珠单抗放化疗的 II 期试验。
J Thorac Oncol. 2020 Feb;15(2):248-257. doi: 10.1016/j.jtho.2019.10.024. Epub 2019 Nov 25.
7
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.度伐利尤单抗化疗和放疗后用于 III 期非小细胞肺癌的总生存。
N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.